Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Pharma
Vaccines
Asia
Cell & Gene Therapy
Drug Delivery
Executives
Manufacturing
Facilities
Recalls
Warning Letters
Marketing
Special Reports
Fierce 50
Special Report
Awards Gala
Resources
Podcasts
Fierce Events
Industry Events
Webinars
Whitepapers
Survey
Events
Subscribe
Subscribe
Pharma
Vaccines
Asia
Cell & Gene Therapy
Drug Delivery
Executives
Manufacturing
Facilities
Recalls
Warning Letters
Marketing
Special Reports
Fierce 50
Special Report
Awards Gala
Resources
Podcasts
Fierce Events
Industry Events
Webinars
Whitepapers
Survey
Events
Subscribe
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Special report
: The Fierce 50 of 2024
Ocaliva
Pharma
Ocaliva's fate looks bleak after FDA releases new briefing docs
For Intercept Pharmaceuticals’ beleaguered liver disease drug Ocaliva, the hits just keep coming.
Fraiser Kansteiner
Sep 11, 2024 4:58pm
FDA approves Gilead's Livdelzi for primary biliary cholangitis
Aug 14, 2024 3:29pm
Alfasigma to take over struggling Intercept
Sep 26, 2023 11:10am
NASH market holds 'enormous untapped potential,' analysts say
Aug 10, 2023 10:00am
UPDATED: Intercept restructures as NASH hopes dashed by FDA
Jun 22, 2023 6:20pm
Intercept still has a long road ahead with Ocaliva in NASH
May 19, 2023 5:29pm
